NCT04083898View on ClinicalTrials.gov

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 3, 2020

Primary Completion Date

March 13, 2023

Study Completion Date

March 7, 2024

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Isatuximab

Isatuximab will be administered on a 28-day cycle

DRUG

Bendamustine

Bendamustine will be administered on a 28-day cycle as follows

DRUG

Prednisone

Prednisone will be administered on a 28-day cycle as follows

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Washington University School of Medicine

OTHER